Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul 26;8(7):223-30.
doi: 10.4252/wjsc.v8.i7.223.

Therapeutic potential of human embryonic stem cells in type 2 diabetes mellitus

Geeta Shroff  1
Affiliations

Therapeutic potential of human embryonic stem cells in type 2 diabetes mellitus

Geeta Shroff. World J Stem Cells. .

Abstract

Aim: To evaluate the safety and efficacy of human embryonic stem cells (hESCs) for the management of type 2 diabetes mellitus (T2DM).

Methods: Patients with a previous history of diabetes and its associated complications were enrolled and injected with hESC lines as per the defined protocol. The patients were assessed using Nutech functional score (NFS), a numeric scoring scale to evaluate the patients for 11 diagnostic parameters. Patients were evaluated at baseline and at the end of treatment period 1 (T1). All the parameters were graded on the NFS scale from 1 to 5. Highest possible grade (HPG) of 5 was considered as the grade of best improvement.

Results: Overall, 94.8% of the patients showed improvement by at least one grade of NFS at the end of T1. For all the 11 parameters evaluated, 54% of patients achieved HPG after treatment. The four essential parameters (improvement in glycated hemoglobin (HbA1c) and insulin level, and fall in number of other oral hypoglycemic drugs with and without insulin) are presented in detail. For HbA1c, 72.6% of patients at the end of T1 met the World Health Organization cut off value, i.e., 6.5% of HbA1c. For insulin level, 65.9% of patients at the end of T1 were able to achieve HPG. After treatment, the improvement was seen in 16.3% of patients who required no more than two medications along with insulin. Similarly, 21.5% of patients were improved as their dosage regimen for using oral drugs was reduced to 1-2 from 5.

Conclusion: hESC therapy is beneficial in patients with diabetes and helps in reducing their dependence on insulin and other medicines.

Keywords: Glycated hemoglobin; Human embryonic stem cells; Insulin; Nutech functional scoring scale; Type 2 diabetes mellitus.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Number of patients assessed for glycated hemoglobin: Before and after the human embryonic stem cell treatment. NFS grades - Grade 1: > 9.0%; Grade 2: 7.0%-9.0%; Grade 3: 6.5%-7.0%; Grade 4: 6.0%-6.5%; Grade 5 (HPG): < 6.0%. HbA1c: Glycated hemoglobin; NFS: Nutech functional score; HPG: Highest possible grade.
Figure 2
Figure 2
Number of patients assessed for insulin: Before and after the human embryonic stem cell treatment. NFS grades - Grade 1: > 100 IU; Grade 2: 80-100 IU; Grade 3: 60-80 IU; Grade 4: 20-60 IU; Grade 5 (HPG): 0-20 IU. NFS: Nutech functional score; HPG: Highest possible grade.
Figure 3
Figure 3
Number of patients assessed for number of medications used without insulin: Before and after the human embryonic stem cell treatment. NFS grades - Grade 1: > 5; Grade 2: < 4; Grade 3: < 3; Grade 4: > 2; Grade 5 (HPG): No medications taken. NFS: Nutech functional score; HPG: Highest possible grade.
Figure 4
Figure 4
Number of patients assessed for number of medications used with insulin: Before and after the human embryonic stem cell treatment. NFS grades - Grade 1: Insulin with > 4 medicines; Grade 2: Insulin with 4 medicines; Grade 3: Insulin with 3 medicines; Grade 4: Insulin with 2 medicines; Grade 5 (HPG): No medications required. NFS: Nutech functional score; HPG: Highest possible grade.
See this image and copyright information in PMC

References

    1. Czubak P, Bojarska-Junak A, Tabarkiewicz J, Putowski L. A modified method of insulin producing cells’ generation from bone marrow-derived mesenchymal stem cells. J Diabetes Res. 2014;2014:628591. - PMC - PubMed
    1. Assady S, Maor G, Amit M, Itskovitz-Eldor J, Skorecki KL, Tzukerman M. Insulin production by human embryonic stem cells. Diabetes. 2001;50:1691–1697. - PubMed
    1. Nikolajczyk BS, Jagannathan-Bogdan M, Shin H, Gyurko R. State of the union between metabolism and the immune system in type 2 diabetes. Genes Immun. 2011;12:239–250. - PMC - PubMed
    1. Khorsandi L, Khodadadi A, Nejad-Dehbashi F, Saremy S. Three-dimensional differentiation of adipose-derived mesenchymal stem cells into insulin-producing cells. Cell Tissue Res. 2015;361:745–753. - PubMed
    1. Barclay RS. 2015. Type 2 diabetes is common and hard to treat. Now, a cure may be on the horizon. Healthline News. Available from: http://www.healthline.com/health-news/combination-of-stem-cell-drug-ther....